-
★
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
(Hinzugefügt: 06.03.2023 um 18:22 Uhr)
https://www.nature.com/articles/s41467-022-33864-y
-
★
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
(Hinzugefügt: 06.03.2023 um 18:22 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800275
-
★
COVID-19: Rekonvaleszentenplasma mit hohem Antikörpertiter halbiert Hospitalisierungsrate
(Hinzugefügt: 23.12.2021 um 16:52 Uhr)
https://www.aerzteblatt.de/nachrichten/130362/COVID-19-Rekonvaleszentenplasma-mit-hohem-Antikoerpertiter-halbiert-Hospitalisierungsrate
-
★
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
(Hinzugefügt: 20.06.2021 um 10:41 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2780916
-
★
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
(Hinzugefügt: 06.04.2021 um 07:21 Uhr)
https://ashpublications.org/blood/article/136/20/2290/463806/Convalescent-plasma-therapy-for-B-cell-depleted
-
★
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
(Hinzugefügt: 07.01.2021 um 05:27 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2033700
-
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
(Hinzugefügt: 05.08.2023 um 12:10 Uhr)
https://ashpublications.org/bloodadvances/article/6/23/5951/486707/Vaccine-boosted-convalescent-plasma-therapy-for
-
COVID-19 convalescent plasma utilization in the United States: data from the National Inpatient Sample
(Hinzugefügt: 10.04.2023 um 14:17 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad185/7092828
-
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
(Hinzugefügt: 07.04.2023 um 17:58 Uhr)
https://www.mdpi.com/1999-4915/15/3/765
-
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates
(Hinzugefügt: 07.04.2023 um 17:57 Uhr)
https://www.mdpi.com/1999-4915/15/3/756
-
COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials
(Hinzugefügt: 06.03.2023 um 18:43 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad088/7048396
-
Twiv 987
(Hinzugefügt: 06.03.2023 um 18:24 Uhr)
https://www.microbe.tv/twiv/
-
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
(Hinzugefügt: 06.03.2023 um 18:24 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2119657
-
Plasma from vaccinated and COVID-19 convalescent subjects as passive immunotherapy against the new Omicron BQ.1.1, XBB, and BF.7 variants
(Hinzugefügt: 06.12.2022 um 16:23 Uhr)
https://www.news-medical.net/news/20221130/Plasma-from-vaccinated-and-COVID-19-convalescent-subjects-as-passive-immunotherapy-against-the-new-Omicron-BQ11-XBB-and-BF7-variants.aspx?fbclid=IwAR1l9HEgfugbdI0c2EbcqqpxeWZt1W7ZUgC7XlW9f5cvSCg6hoy07B1PvMw
-
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
(Hinzugefügt: 06.12.2022 um 16:05 Uhr)
https://www.biorxiv.org/content/10.1101/2022.11.25.517977v2
-
Recombinant human plasma gelsolin reverses increased permeability of the blood–brain barrier induced by the spike protein of the SARS-CoV-2 virus
(Hinzugefügt: 29.11.2022 um 16:23 Uhr)
https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022-02642-4
-
Limitations on PassItOn Design and Execution Should Temper Negative Conclusions
(Hinzugefügt: 05.11.2022 um 15:46 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0012369222036443
-
Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19
(Hinzugefügt: 26.10.2022 um 14:10 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2784914
-
Nucleocapsid-specific antibody function is associated with therapeutic benefit from Covid-19 Convalescent plasma therapy
(Hinzugefügt: 26.10.2022 um 14:07 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(22)00370-6
-
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
(Hinzugefügt: 03.04.2022 um 17:10 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2119657
-
Once Viewed as a Promising COVID-19 Treatment, Convalescent Plasma Falls Out of Favor
(Hinzugefügt: 11.03.2022 um 10:44 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2790074
-
High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
(Hinzugefügt: 06.03.2022 um 18:39 Uhr)
https://www.medrxiv.org/content/10.1101/2022.03.01.22271662v1
-
Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
(Hinzugefügt: 17.02.2022 um 07:34 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788376
-
High-Dose Convalescent Plasma for Treatment of Severe COVID-19
(Hinzugefügt: 17.02.2022 um 07:26 Uhr)
https://wwwnc.cdc.gov/eid/article/28/3/21-2299_article
-
Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19
(Hinzugefügt: 17.02.2022 um 06:41 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788377
-
Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
(Hinzugefügt: 17.02.2022 um 06:41 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788376
-
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
(Hinzugefügt: 14.02.2022 um 16:42 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.10.21267485v1
-
Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children
(Hinzugefügt: 14.02.2022 um 16:41 Uhr)
https://insight.jci.org/articles/view/151518
-
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
(Hinzugefügt: 10.01.2022 um 13:01 Uhr)
https://www.nature.com/articles/d41586-021-03846-z?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature
-
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
(Hinzugefügt: 26.12.2021 um 10:38 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.10.21267485v1
-
Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
(Hinzugefügt: 25.12.2021 um 15:37 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.20.21268134v1
-
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
(Hinzugefügt: 21.12.2021 um 12:40 Uhr)
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2787090
-
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
(Hinzugefügt: 18.12.2021 um 14:53 Uhr)
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2787090
-
SARS-CoV-2 Omicron Spike Glycoprotein Receptor Binding Domain Exhibits Super-Binder Ability with ACE2 but not Convalescent Monoclonal Antibody
(Hinzugefügt: 13.12.2021 um 11:01 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.09.471885v1
-
COVID-19: WHO rät von Behandlung mit Rekonvaleszentenserum ab
(Hinzugefügt: 07.12.2021 um 17:02 Uhr)
https://www.aerzteblatt.de/nachrichten/129795/COVID-19-WHO-raet-von-Behandlung-mit-Rekonvaleszentenserum-ab
-
SARS-CoV-2: Serumtherapie kommt bei Intensivpatienten zu spät
(Hinzugefügt: 06.10.2021 um 06:28 Uhr)
https://www.aerzteblatt.de/nachrichten/127888/SARS-CoV-2-Serumtherapie-kommt-bei-Intensivpatienten-zu-spaet
-
Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19
(Hinzugefügt: 05.10.2021 um 08:21 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2784914
-
A highly potent antibody effective against SARS-CoV-2 variants of concern
(Hinzugefügt: 29.09.2021 um 09:52 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01278-X
-
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
(Hinzugefügt: 14.09.2021 um 07:50 Uhr)
https://www.nature.com/articles/s41591-021-01488-2
-
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
(Hinzugefügt: 24.08.2021 um 16:27 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2103784
-
SARS-CoV-2: Serumtherapie scheitert in weiterer Studie
(Hinzugefügt: 24.08.2021 um 15:10 Uhr)
https://www.aerzteblatt.de/nachrichten/126529/SARS-CoV-2-Serumtherapie-scheitert-in-weiterer-Studie
-
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
(Hinzugefügt: 24.08.2021 um 15:03 Uhr)
https://www.pnas.org/content/118/36/e2103154118
-
Überantibodies From Recovered COVID-19 Patients Could Spur New Therapeutics and Vaccines
(Hinzugefügt: 06.08.2021 um 11:37 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2782673
-
Plasma from patients with bacterial sepsis or severe COVID-19 induces suppressive myeloid cell production from hematopoietic progenitors in vitro
(Hinzugefügt: 09.07.2021 um 19:21 Uhr)
https://stm.sciencemag.org/content/13/598/eabe9599
-
Behandlung von COVID-19 mit Rekonvaleszentenplasma: Uneinheitliche Studienlage erschwert die Bewertung
(Hinzugefügt: 09.07.2021 um 18:18 Uhr)
https://www.aerzteblatt.de/nachrichten/125459/Behandlung-von-COVID-19-mit-Rekonvaleszentenplasma-Uneinheitliche-Studienlage-erschwert-die-Bewertung
-
COVID-19: Serumtherapie kann bei hämatologischen Krebspatienten erfolgreich sein
(Hinzugefügt: 21.06.2021 um 13:29 Uhr)
https://www.aerzteblatt.de/nachrichten/124857/COVID-19-Serumtherapie-kann-bei-haematologischen-Krebspatienten-erfolgreich-sein
-
Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries
(Hinzugefügt: 20.06.2021 um 17:34 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00211-X/fulltext
-
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
(Hinzugefügt: 22.05.2021 um 17:06 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00897-7/fulltext
-
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19
(Hinzugefügt: 20.05.2021 um 06:30 Uhr)
https://www.jci.org/articles/view/150646
-
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
(Hinzugefügt: 16.05.2021 um 10:14 Uhr)
https://www.sciencedirect.com/science/article/pii/S0140673621008977
-
SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies
(Hinzugefügt: 07.05.2021 um 06:45 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.04.442701v1
-
Podcast zu Plasma
(Hinzugefügt: 05.04.2021 um 13:17 Uhr)
https://www.microbe.tv/twiv/twiv-739/
-
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
(Hinzugefügt: 03.04.2021 um 06:00 Uhr)
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00030-6/fulltext
-
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
(Hinzugefügt: 29.03.2021 um 18:32 Uhr)
https://www.nature.com/articles/s41586-021-03471-w
-
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
(Hinzugefügt: 18.03.2021 um 05:50 Uhr)
https://www.nature.com/articles/s41591-021-01285-x.epdf?sharing_token=UWhpgianfTQvLwMn36yPldRgN0jAjWel9jnR3ZoTv0PHrWGE1ztRK1Cl8-gyfXxc2yIVk-fIWCgfjx90gIFEtbWZrnv7a9KCSgobGE1-pF33xtOTF0BnptLJYCCT6aTwpimmmwt3h_raUZJ9Y715p_9YSyaG_4noGqF_kwEzR4k%3D
-
High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients
(Hinzugefügt: 11.03.2021 um 14:36 Uhr)
https://www.medrxiv.org/content/10.1101/2021.03.08.21252775v1
-
Convalescent Plasma Strikes Out As COVID-19 Treatment
(Hinzugefügt: 10.03.2021 um 20:15 Uhr)
https://www.npr.org/sections/health-shots/2021/03/10/975365309/convalescent-plasma-strikes-out-as-covid-19-treatment
-
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
(Hinzugefügt: 07.03.2021 um 08:08 Uhr)
https://www.nature.com/articles/s41591-021-01294-w.epdf?sharing_token=NMzr0CrnSTROByBX3yrGp9RgN0jAjWel9jnR3ZoTv0MKFcwKvclRE6Ur7Or5B-WrXWig3cNNITxe9Drg9PisaQsSwyzTTJpiDX4Rd1Ok6McWWcPhIoUVjdB-ZQrQbHecEorijaOEn0cQ6_9KW_Op_6HGR9sLW-8zyMWltEP3Tkc%3D
-
NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
(Hinzugefügt: 03.03.2021 um 08:32 Uhr)
https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms
-
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19
(Hinzugefügt: 27.02.2021 um 07:00 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777060
-
Study finds short window for donating convalescent plasma to COVID-19 patients
(Hinzugefügt: 26.02.2021 um 03:41 Uhr)
https://news.psu.edu/story/648997/2021/02/25/research/study-finds-short-window-donating-convalescent-plasma-covid-19
-
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates
(Hinzugefügt: 24.02.2021 um 16:43 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00151-0
-
BIOTEST AUS DREIEICH: Blutplasma gegen Covid-19
(Hinzugefügt: 19.02.2021 um 10:50 Uhr)
https://www.faz.net/aktuell/rhein-main/blutplasma-gegen-corona-infektion-biotest-aus-dreieich-17205002.html
-
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
(Hinzugefügt: 14.02.2021 um 10:23 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33571168/
-
Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
(Hinzugefügt: 12.02.2021 um 08:16 Uhr)
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009165
-
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
(Hinzugefügt: 10.02.2021 um 09:48 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2031893
-
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
(Hinzugefügt: 10.02.2021 um 09:36 Uhr)
https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell-host-microbe%2Ffulltext%2FS1931-3128%2821%2900082-2&rc=0
-
SARS-CoV-2: FDA schränkt Verwendung von Serumtherapie ein
(Hinzugefügt: 10.02.2021 um 09:30 Uhr)
https://www.aerzteblatt.de/nachrichten/120983/SARS-CoV-2-FDA-schraenkt-Verwendung-von-Serumtherapie-ein
-
Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19
(Hinzugefügt: 06.02.2021 um 08:55 Uhr)
https://www.medrxiv.org/content/10.1101/2021.02.05.21250953v1
-
SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants
(Hinzugefügt: 30.01.2021 um 11:26 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.19.20248567v2.full.pdf
-
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein
(Hinzugefügt: 29.01.2021 um 08:16 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.27.428534v1
-
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
(Hinzugefügt: 28.01.2021 um 13:55 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33485405/
-
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
(Hinzugefügt: 28.01.2021 um 13:53 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00044-5
-
Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma
(Hinzugefügt: 27.01.2021 um 17:55 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.26.21250224v1
-
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
(Hinzugefügt: 27.01.2021 um 17:53 Uhr)
https://science.sciencemag.org/content/early/2021/01/22/science.abf9302.full
-
Vaccination Against the New Variants: Real-World Data
(Hinzugefügt: 27.01.2021 um 17:52 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2021/01/27/vaccination-against-the-new-variants-real-world-data
-
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
(Hinzugefügt: 27.01.2021 um 17:51 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.25.428137v2.full.pdf+html
-
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
(Hinzugefügt: 24.01.2021 um 09:12 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1
-
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
(Hinzugefügt: 20.01.2021 um 20:18 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1
-
SARS-CoV-2: Serumtherapie enttäuscht in der RECOVERY-Studie
(Hinzugefügt: 19.01.2021 um 07:00 Uhr)
https://www.aerzteblatt.de/nachrichten/120274/SARS-CoV-2-Serumtherapie-enttaeuscht-in-der-RECOVERY-Studie
-
RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19
(Hinzugefügt: 16.01.2021 um 08:34 Uhr)
https://www.recoverytrial.net/news/statement-from-the-recovery-trial-chief-investigators-15-january-2021-recovery-trial-closes-recruitment-to-convalescent-plasma-treatment-for-patients-hospitalised-with-covid-19
-
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
(Hinzugefügt: 14.01.2021 um 05:05 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2033700
-
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
(Hinzugefügt: 14.01.2021 um 05:04 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2031893
-
Enhancement versus Neutralization by SARS-CoV-2 Antibodies from A Convalescent Donor Associates with Distinct Epitopes on the Receptor-Binding Domain
(Hinzugefügt: 13.01.2021 um 08:28 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00012-7
-
Update on recruitment to convalescent plasma and tocilizumab treatment arms
(Hinzugefügt: 12.01.2021 um 07:36 Uhr)
https://www.recoverytrial.net/news/update-on-recruitment-to-convalescent-plasma-and-tocilizumab-treatment-arms-statement-from-the-recovery-trial-chief-investigators
-
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
(Hinzugefügt: 11.01.2021 um 19:24 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v3
-
Trial of COVID-19 blood plasma finds no benefit in severely ill patients
(Hinzugefügt: 11.01.2021 um 19:06 Uhr)
https://www.reuters.com/article/us-health-coronavirus-plasma-idUSKBN29G1JZ
-
COVID-19: Hochdosierte Serumtherapie in Frühphase der Erkrankung effektiv
(Hinzugefügt: 09.01.2021 um 10:25 Uhr)
https://www.aerzteblatt.de/nachrichten/119983/COVID-19-Hochdosierte-Serumtherapie-in-Fruehphase-der-Erkrankung-effektiv
-
COVID research updates: Quick treatment with antibody-laden blood cuts risk of severe COVID
(Hinzugefügt: 08.01.2021 um 18:34 Uhr)
https://www.nature.com/articles/d41586-020-00502-w
-
Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors
(Hinzugefügt: 08.01.2021 um 09:49 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.06.20249035v1
-
SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
(Hinzugefügt: 31.12.2020 um 11:09 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.28.424451v1
-
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma
(Hinzugefügt: 23.12.2020 um 08:48 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.20.423708v1
-
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
(Hinzugefügt: 20.12.2020 um 09:36 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.16.20248294v1
-
The Assessment of Convalescent Plasma Efficacy against COVID-19
(Hinzugefügt: 19.12.2020 um 09:20 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(20)30025-8
-
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies
(Hinzugefügt: 15.12.2020 um 19:20 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33314018/
-
Convalescent Plasma-Mediated Resolution of COVID-19 in a Patient with Humoral Immunodeficiency
(Hinzugefügt: 08.12.2020 um 09:12 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30211-1
-
Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC
(Hinzugefügt: 07.12.2020 um 07:51 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.02.20242909v1
-
Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial
(Hinzugefügt: 30.11.2020 um 08:59 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1
-
SARS-CoV-2: Serumtherapie bleibt in randomisierter Studie ohne Wirkung
(Hinzugefügt: 27.11.2020 um 10:56 Uhr)
https://www.aerzteblatt.de/nachrichten/118738/SARS-CoV-2-Serumtherapie-bleibt-in-randomisierter-Studie-ohne-Wirkung
-
Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
(Hinzugefügt: 25.11.2020 um 09:27 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2031304
-
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
(Hinzugefügt: 23.11.2020 um 16:27 Uhr)
https://ashpublications.org/blood/article/136/20/2290/463806/Convalescent-plasma-therapy-for-B-cell-depleted
-
Prevention of severe COVID-19 in the elderly by early high-titer plasma
(Hinzugefügt: 22.11.2020 um 09:55 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.20.20234013v1
-
longitudinal study with proposals for better quality of CCP collections.
(Hinzugefügt: 17.11.2020 um 08:57 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.12.20230391v1
-
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
(Hinzugefügt: 13.11.2020 um 08:21 Uhr)
https://stm.sciencemag.org/content/early/2020/11/02/scitranslmed.abd3876.full
-
Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review
(Hinzugefügt: 11.11.2020 um 08:34 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.08.20224790v1
-
T-cells Are Rapidly Expanded for Therapeutic Use
(Hinzugefügt: 05.11.2020 um 07:37 Uhr)
https://ashpublications.org/blood/article/doi/10.1182/blood.2020008488/469713/SARS-CoV-2-specific-T-cells-Are-Rapidly-Expanded
-
Antibodies in serum of convalescent patients following mild COVID‐19 do not always prevent virus‐receptor binding
(Hinzugefügt: 04.11.2020 um 19:11 Uhr)
https://onlinelibrary.wiley.com/doi/full/10.1111/all.14523
-
Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
(Hinzugefügt: 04.11.2020 um 18:56 Uhr)
https://ajp.amjpathol.org/article/S0002-9440(20)30370-9/fulltext
-
senkt Sterblichkeit nur in der Frühphase der Erkrankung
(Hinzugefügt: 04.11.2020 um 18:44 Uhr)
https://www.aerzteblatt.de/nachrichten/115601/COVID-19-Plasmatherapie-senkt-Sterblichkeit-nur-in-der-Fruehphase-der-Erkrankung
-
Antiphospholipid-Antikörper könnten thrombotische Komplikationen (und Versagen einer Serumtherapie) erklären
(Hinzugefügt: 03.11.2020 um 20:23 Uhr)
https://www.aerzteblatt.de/nachrichten/117998/COVID-19-Antiphospholipid-Antikoerper-koennten-thrombotische-Komplikationen-(und-Versagen-einer-Serumtherapie)-erklaeren
-
keine Wirksamkeit
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.bmj.com/content/371/bmj.m4072
-
Plasma
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.biorxiv.org/content/10.1101/2020.10.26.355107v1
-
Convalescent plasma treatment - Studie
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/s41591-020-1088-9
-
Rekonvaleszentenplasma
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.bmj.com/content/371/bmj.m3939
-
bei B-Zell Mangel
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://ashpublications.org/blood/article/doi/10.1182/blood.2020008423/463806/Convalescent-plasma-therapy-for-B-cell-depleted